Literature DB >> 7603979

Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection.

L P Seung1, D A Rowley, P Dubey, H Schreiber.   

Abstract

During tumor progression, variants may arise that grow more vigorously. The fate of such variants depends upon the balance between aggressiveness of the variant and the strength of the host immunity. Although enhancing host immunity to cancer is a logical objective, eliminating host factors necessary for aggressive growth of the variant should also be considered. The present study illustrates this concept in the model of a spontaneously occurring, progressively growing variant of an ultraviolet light-induced tumor. The variant produces chemotactic factors that attract host leukocytes and is stimulated in vitro by defined growth factors that can be produced or induced by leukocytes. This study also shows that CD8+ T-cell immunity reduces the rate of tumor growth; however, the variant continues to grow and kills the host. Treatment with a monoclonal anti-granulocyte antibody that counteracts the infiltration of the tumor cell inoculum by non-T-cell leukocytes did not interfere with the CD8+ T-cell-mediated immune response but resulted in rejection of the tumor challenge, indicating a synergy between CD8+ T-cell-mediated immunity and the inhibition of paracrine stimulation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7603979      PMCID: PMC41496          DOI: 10.1073/pnas.92.14.6254

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Major histocompatibility complex class I and unique antigen expression by murine tumors that escaped from CD8+ T-cell-dependent surveillance.

Authors:  P L Ward; H K Koeppen; T Hurteau; D A Rowley; H Schreiber
Journal:  Cancer Res       Date:  1990-07-01       Impact factor: 12.701

2.  Modulation of in vivo immune response by selective depletion of neutrophils using a monoclonal antibody, RP-3. II. Inhibition by RP-3 treatment of mononuclear leukocyte recruitment in delayed-type hypersensitivity to sheep red blood cells in rats.

Authors:  C Kudo; T Yamashita; M Terashita; F Sendo
Journal:  J Immunol       Date:  1993-05-01       Impact factor: 5.422

3.  Modulation of in vivo immune response by selective depletion of neutrophils using a monoclonal antibody, RP-3. I. Inhibition by RP-3 treatment of the priming and effector phases of delayed type hypersensitivity to sheep red blood cells in rats.

Authors:  C Kudo; T Yamashita; A Araki; M Terashita; T Watanabe; M Atsumi; M Tamura; F Sendo
Journal:  J Immunol       Date:  1993-05-01       Impact factor: 5.422

4.  Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells.

Authors:  K Hestdal; F W Ruscetti; J N Ihle; S E Jacobsen; C M Dubois; W C Kopp; D L Longo; J R Keller
Journal:  J Immunol       Date:  1991-07-01       Impact factor: 5.422

5.  Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4.

Authors:  L Chen; S Ashe; W A Brady; I Hellström; K E Hellström; J A Ledbetter; P McGowan; P S Linsley
Journal:  Cell       Date:  1992-12-24       Impact factor: 41.582

6.  Abrogation of tumor-inhibitory MRC-OX8+ (CD8+) effector T-cell generation in rats by selective depletion of neutrophils in vivo using a monoclonal antibody.

Authors:  E Tanaka; F Sendo
Journal:  Int J Cancer       Date:  1993-04-22       Impact factor: 7.396

7.  Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA.

Authors:  J Trojan; T R Johnson; S D Rudin; J Ilan; M L Tykocinski; J Ilan
Journal:  Science       Date:  1993-01-01       Impact factor: 47.728

8.  Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity.

Authors:  B Gansbacher; K Zier; B Daniels; K Cronin; R Bannerji; E Gilboa
Journal:  J Exp Med       Date:  1990-10-01       Impact factor: 14.307

9.  CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help.

Authors:  F A Harding; J P Allison
Journal:  J Exp Med       Date:  1993-06-01       Impact factor: 14.307

View more
  63 in total

1.  Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells.

Authors:  V Bronte; E Apolloni; A Cabrelle; R Ronca; P Serafini; P Zamboni; N P Restifo; P Zanovello
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

2.  Myeloid suppressor cells induced by retinal pigment epithelial cells inhibit autoreactive T-cell responses that lead to experimental autoimmune uveitis.

Authors:  Zhidan Tu; Yan Li; Dawn Smith; Catherine Doller; Sunao Sugita; Chi-Chao Chan; Shiguang Qian; John Fung; Rachel R Caspi; Lina Lu; Feng Lin
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-02-23       Impact factor: 4.799

Review 3.  Targeting stroma to treat cancers.

Authors:  Boris Engels; Donald A Rowley; Hans Schreiber
Journal:  Semin Cancer Biol       Date:  2011-12-24       Impact factor: 15.707

Review 4.  Adoptive immunotherapy for cancer: building on success.

Authors:  Luca Gattinoni; Daniel J Powell; Steven A Rosenberg; Nicholas P Restifo
Journal:  Nat Rev Immunol       Date:  2006-05       Impact factor: 53.106

Review 5.  Role of myeloid-derived suppressor cells in allogeneic hematopoietic cell transplantation.

Authors:  Brent H Koehn; Bruce R Blazar
Journal:  J Leukoc Biol       Date:  2017-02-01       Impact factor: 4.962

Review 6.  Advancements in immune tolerance.

Authors:  Ping-Ying Pan; Junko Ozao; Zuping Zhou; Shu-Hsia Chen
Journal:  Adv Drug Deliv Rev       Date:  2007-10-05       Impact factor: 15.470

Review 7.  Tumor-infiltrating lymphocytes in melanoma.

Authors:  Sylvia Lee; Kim Margolin
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

Review 8.  Exploiting the curative potential of adoptive T-cell therapy for cancer.

Authors:  Christian S Hinrichs; Steven A Rosenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

9.  Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination.

Authors:  Carmela De Santo; Paolo Serafini; Ilaria Marigo; Luigi Dolcetti; Manlio Bolla; Piero Del Soldato; Cecilia Melani; Cristiana Guiducci; Mario P Colombo; Manuela Iezzi; Piero Musiani; Paola Zanovello; Vincenzo Bronte
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

Review 10.  Altered macrophage differentiation and immune dysfunction in tumor development.

Authors:  Antonio Sica; Vincenzo Bronte
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.